Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral dosage form for oral use. It is indicated for the management of acute coronary syndrome and for reducing thrombotic cardiovascular events after myocardial infarction, as well as for secondary prevention of atherothrombotic events. GNH USA supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kogavant (ticagrelor) is an antiplatelet agent used in several cardiovascular conditions. - Acute coronary syndrome (ACS): reduces the risk of cardiovascular death, myocardial infarction and stroke in patients presenting with ACS. - Post‑myocardial infarction: lowers the incidence of thrombotic cardiovascular events after an MI. - Secondary prevention of atherothrombotic events: helps prevent recurrent ischemic events in patients with established atherosclerotic disease.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspnea: shortness of breath, often occurring early in therapy. - Bleeding: including bruising, nosebleeds, gastrointestinal hemorrhage. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe bleeding: intracranial or life‑threatening hemorrhage. - Hypersensitivity reactions: rash, angioedema, anaphylaxis. - Elevated serum uric acid: may precipitate gout attacks.

Before initiating ticagrelor therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal impairment: assess renal function and consider dose adjustment. - Hepatic disease: use with caution in patients with moderate to severe liver dysfunction. - Concomitant anticoagulants: increased bleeding risk; monitor coagulation parameters. - History of bleeding disorders: evaluate bleeding risk before prescribing. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ticagrelor can interact with several medicines, altering its antiplatelet effect or increasing bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ticagrelor plasma levels and heighten bleeding. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): additive anticoagulant effect; monitor for signs of bleeding. - NSAIDs or aspirin: combined use raises gastrointestinal bleeding risk. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure; consider dose reduction.